Nicotine responses in hypersensitive and knockout α4 mice account for tolerance to both hypothermia and locomotor suppression in wild-type mice by Tapper, Andrew R. et al.
1Nicotine responses in hypersensitive and knockout 4 
mice account for tolerance to both hypothermia and 
locomotor suppression in wild-type mice
Andrew R. Tapper1,3, Sheri L. McKinney1, Michael J. Marks2,and Henry A. 
Lester1
1Division of Biology, California Institute of Technology, Pasadena, CA 91125
2Institute for Behavioral Genetics, University of Colorado, Boulder, CO 80309
3Brudnick Neuropsychiatric Research Institute, University of Massachusetts Medical School, 
Worcester, MA 01604
Brief Title: Nicotine tolerance predicted from mutants
*Corresponding author: Henry A. Lester, lester@caltech.edu
156-29 Caltech, Pasadena CA 91125
phone 626-395-4946; fax  626-564-8709
Acknowledgements:
Funding from NIH NRSA (AT), DA-17279, DA19375, California TRDRP, and Philip 
Morris USA / International is gratefully acknowledged.  
Key words: nicotine, addiction, nicotinic receptors, hypothermia, locomotion
Page 1 of 18Articles in PresS. Physiol Genomics (August 21, 2007). doi:10.1152/physiolgenomics.00063.2007 
 Copyright © 2007 by the American Physiological Society.
2Abstract
Nicotinic receptors containing the 4 subunit (4* nAChRs) have high 
sensitivity and are widely expressed in the CNS, yet their contributions to
behavioral tolerance, a hallmark of nicotine dependence, are unclear.  To 
evaluate the contribution of 4*- and non-4 nAChRs in the development of 
tolerance to hypothermia and locomotor suppression, 4 knockout (KO),
hypersensitive Leu9’Ala 4 knock-in, and wild-type (WT) mice received daily 
nicotine injections, and their behaviors were compared.  Repeated selective 
activation of 4* nAChRs in Leu9’Ala mice produced profound tolerance to 
hypothermia over 7 days, whereas no tolerance was observed in 4 KO animals.  
The summed time course and temperature response (after appropriate 
normalizations) from these two mutant mouse strains resembled the time course 
of WT tolerance.  In addition, daily selective activation of 4* nAChRs elicited 
locomotor activation in Leu9’Ala mice, but nicotine suppressed activity in 4 KO 
mice and this did not change with daily drug exposure.  Again, appropriately 
combined responses from the two mutant strains resembled the biphasic 
nicotine-induced activity in WT animals.  Thus, by analyzing nicotinic responses 
in two complementary mouse lines, one lacking 4* nAChRs, the other 
expressing hypersensitive 4* nAChRs, one can accurately separate non-4
nAChR responses from 4 nAChR responses, and one can also account for WT
tolerance to both hypothermia and locomotor suppression.  Our study suggests a 
new paradigm for bridging the gap between genetic manipulation of a single 
receptor and whole-animal behavioral studies, and shows that activation of 4* 
nAChRs is both necessary and sufficient for the expression of tolerance.
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Neuronal nAChRs are cation-selective ligand-gated ion-channels that are 
activated by the endogenous ligand, acetylcholine, as well as the naturally 
occurring alkaloid found in tobacco, nicotine.  At present, 12 neuronal nicotinic 
acetylcholine receptor subunits have been identified (2-10 and 2-4)(12). The 
majority of subunits form functional heteromeric pentamers while a subset may 
form homomeric receptors.  Thus, a myriad of nAChR subtypes may exist. 
Identification of nAChR subtypes specifically involved in dependence-related 
behaviors will give insights into the mechanism of nicotine dependence and will 
help to identify specific neural circuits that participate in addiction(17).
Previously, we have engineered and characterized a mouse line 
expressing a single point mutation in the M2 domain of the 4 nAChR subunit(3, 
7, 16).  This mutation, Leu9’Ala, renders 4* nAChRs hypersensitive to nicotine
by ~50-fold compared with wild-type (WT) mice.  In the absence of specific 
agonists, this “knock-in” Leu9’Ala mouse line allows for the selective activation of 
4* receptors with small doses of nicotine that do not activate other nAChR 
subtypes.  Leu9’Ala mice exhibit dependence-related behaviors including 
tolerance and sensitization when challenged with daily injections of nicotine at 
doses that have little affect in wild-type animals. However, locomotor and
hypothermia tolerance profiles in Leu9’Ala mice differ from those of wild-type
mice tested at 50-fold higher nicotine doses, indicating that 4* nAChR-mediated 
responses in WT mice are likely confounded by responses due to activation of 
other non-4* nAChR subtypes. Indeed, nicotine doses required to elicit 
physiological responses in wild-type mice, and those doses that occur in 
smokers, activate multiple receptor subtypes(6, 19).  
Mouse strains have also been developed that lack 4 nAChR receptors(9, 
15).  In this report, we utilize these two, complementary mouse models to 
evaluate the role of 4* nAChRs in the response to nicotine.  The Leu9’Ala line
can be used to selectively activate 4* nAChRs with low doses of nicotine. The 
4-null or knockout line (4KO) allows us to determine the response to nicotine 
that is mediated by non-4* nAChRs.  We ask whether experimental data can be 
subjected to simple algorithms that account for the WT nicotine effects based on 
responses from these two mutant strains. A comparison of nicotine-mediated 
effects in these two lines does implicate 4* nAChRs in a hallmark of 
dependence: tolerance.
Methods
Mice
All experiments were conducted in accordance with the guidelines for care and 
use of animals provided by the National Institutes of Health, as well as with an 
approved animal protocol from the California Institute of Technology animal care 
and use committee.  Animals were kept on a standard 12 hr light/dark cycle and 
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4given food and water ad libitum. To minimize variability in responses due to 
genetic background differences, mice from both Leu9’Ala and 4 KO lines were 
back-crossed at least eight generations to the C57BL/6J strain with the exception 
of animals used for figure 3A and B which were back-crossed at least 3 
generations (8).
Telemetry Probes
Vital View PDT-4000 temperature and activity telemetric probes were used
(Respironics, Inc.).  For implantation, mice were anesthetized with halothane, 
and a 1 cm incision was made at the back of the neck.  Probes were inserted 
subcutaneously into the back.  The incision was sealed with surgical glue and the 
mice were allowed to recover for 48 hr.  Temperature and activity data were 
acquired at 30 sec intervals using Vital View software and analyzed in Origin. 
Nicotine Administration
Nicotine base was used in all behavioral experiments and administered through 
i.p. injection with 1 ml syringes.  Nicotine, mecamylamine, and SCH29930 were 
obtained from Sigma. Animals were injected daily with saline for at least three
days prior to the start of each temperature and activity experiment, and average 
temperature changes for saline injections were < 0.2 ºC. Pre-injection with 
SCH29930 did not produce significant temperature changes compared to saline.
All activity and body temperature measurements were recorded in the home 
cage.
Calculations
Predicted hypothermia tolerance profiles
We assume that, in WT mice, there are at least two components of 
nicotine-induced hypothermia, and that these are mediated by at least two 
nAChR subtypes whose pathways are parallel and additive.  We therefore write, 
NAWT TTT += , where WTT is the total change in body temperature for WT,
AT  is the change in body temperature due to activation of 4* nAChRs, and 
NT  is the change in body temperature due to activation of non-4* nAChRs.
For Leu9’Ala mice injected with 0.015 mg/kg nicotine, ATT = AlaLeu9' ; whereas, 
for 4 KO mice injected with 2 mg/kg nicotine, NTT = 4KO .  Thus, we predict 
that 4KOAlaLeu9' TTTWT +=  for each daily exposure to nicotine.
To measure tolerance to nicotine-induced hypothermia, we injected 
Leu9’Ala, 4 KO, and WT mice with 0.015 mg/kg, 2 mg/kg nicotine, and 2 mg/kg 
nicotine, (i.p.), respectively, once daily over the course of seven days.  WT mice 
received 2 mg/kg nicotine for comparison because this dose would be expected 
to maximally activate high-sensitivity 4* nAChRs while also activating lower-
sensitivity, non-4* nAChRs, presumably activated by the same dose in 4 KO 
mice. Doses > 2 mg/kg induce seizures in appreciable numbers of mice and, 
therefore, were not tested. This strategy could be confounded by compensatory 
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5or developmental changes in expression of other nAChR subtypes in Leu9’Ala or 
4 KO mice.  However, to date, radioligand binding and in situ hybridization 
analyses have revealed no such changes(3, 15, 16). 
We measured the maximal change in temperature (usually negative) 
within 40 min after a nicotine injection on day n; usually this extremum occurred 
at ~25 min. We averaged these changes for all mice of each genotype to obtain 
N)(nT , AnT )( , WTnT )(  on each day n.  We then define 
( )NANN TTnTnt )1()1(/)()( += , (1)
( )NAAA TTnTnt )1()1(/)()( += , (2)
WTWTWT TnTnt )1(/)()( = . (3)
In most cases, 0)(,)(,)(1 <<
 WTAN ntntnt .
Thus, we predict WT activity after a nicotine injection on day n :   
ANWT ntntnt )()()( += (4)
Predicted locomotor profiles
We assume there are at least two nicotine-induced components that affect 
locomotor activity in WT mice, an 4* nAChR and non-4* nAChR component.  
We write, ( )ANBWBL WTWT •== , where L is total locomotor activity after nicotine 
exposure, and B  is the average baseline activity over 30 minutes immediately 
following a saline injection. A , N , and W  are positive dimensionless 
parameters.  A describes the effect of 4* nAChR activation on activity and 
equals unity for the KO strain.  N describes the non-4* nAChR effect on activity
and equals unity for nicotine doses too low to activate non-4 receptors.  The 
parameter W is defined similarly for WT mice.  Because activity is affected in 
opposite directions for 4 KO and Leu9’Ala strains but cannot have a negative 
value, multiplication is more appropriate than simple addition for combining the 
two processes; thus ANW = .  For Leu9’Ala mice injected with 0.015 mg/kg 
nicotine ABL AA = .  Then AA BLA = .  For 4 KO mice injected with 2 mg/kg 
nicotine, NBL NN = .  Then, NN BTN = .  
To measure locomotor effects of nicotine, we injected Leu9’Ala, 4 KO, and WT 
mice with 0.015 mg/kg, 2 mg/kg nicotine, and 2 mg/kg nicotine, (i.p.), 
respectively, once daily over the course of six days.  We averaged total activity 
during 30 min immediately after each nicotine injection for all mice of each 
genotype to obtain ( )AnL , ( )NnL , and ( )WTnL on each day, n .  Then:
( )nNBnL NN =)( (5)
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6( )nABnL AA =)( (6) 
Thus, one predicts WT activity after a nicotine injection on day n :   
( ) ( )nNnABnL WTWT =)( (7)
Statistical tests
Significance in all experiments was determined by one-way ANOVA followed by 
post-hoc analysis (Tukey test unless otherwise stated).
Results
Hypothermia
Acute nicotine injection elicits hypothermia in mice(13).  Figure 1A 
illustrates the dose-response relationships for nicotine-induced hypothermia in 
WT, Leu9’Ala, and 4 KO mice.  Previously, we reported that Leu9’Ala exhibit a 
leftward-shifted dose response relationship compared to WT(16).  We repeat this 
result here, using Leu9’Ala mice on a congenic, C57BL/6J background.  The 
congenic Leu9’Ala mice are approximately 50-fold more sensitive than WT to the 
hypothermic effects of nicotine, similar to the previously studied Leu9’Ala mutant 
line on a mixed genetic background.  
In 4 knockout mice, 0.5 mg/kg nicotine does not elicit hypothermia; and 
this is significantly different from the nicotine effect in WT animals (1.09 + 0.070 C
in 4 KOs compared to -2.08 + 0.3900 C in WT, p < 0.001, F1,14 = 97.4, Fig. 1A).  
When challenged with higher doses of nicotine, 1 or 2 mg/kg, 4 KO mice do 
exhibit hypothermia although at significantly less levels than WT mice challenged 
with the same dose.  It is not possible to provide ED50 values because two of the
dose-effect relations do not saturate at high nicotine doses; instead, we present 
nicotine doses that induced a 20 C decrease:  0.009, 0.4, and 1.7 mg/kg, for L9’A, 
WT, and 4 respectively.  
We previously reported that in WT and Leu9’Ala mice, the non-competitive 
nicotinic antagonist, mecamylamine, significantly blocked nicotine-induced 
hypothermia (16).  We now report that mecamylamine also blocked nicotine-
induced hypothermia in 4 KO mice.  The body temperature of 4 KO mice
challenged with 2 mg/kg nicotine 15 min after a saline injection decreased 2.74 +
0.310 C  while body temperature dropped only 0.80 + 0.110 C in 4 KO mice 
pretreated with 2 mg/kg mecamylamine (p<0.001, F1, 9 =29.4, Fig. 1B).  The 
peripheral nicotinic receptor antagonist, hexamethonium, did not significantly 
block nicotine induced hypothermia in either 4 KO or Leu9’ala mice (1 mg/kg, 
data not shown, NS, n = 6 per genotype).  
Direct and indirect dopamine agonists elicit hypothermia in rodents(1, 2),
and previously, we found that Leu9’Ala mice express hypersensitive 4* nAChRs 
in midbrain dopaminergic neurons, suggesting that nicotine-induced hypothermia 
may have a dopamine-dependent component(16).  The D1 antagonist 
SCH29930 significantly attenuates nicotine induced hypothermia in Leu9’Ala 
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7animals (sal + 0.03 mg/kg nicotine = -3.26 + 0.460 C compared to -1.60 + 0.300 C  
in mice treated with 2 mg/kg SCH29930 + 0.03 mg/kg nicotine, p < 0.01, F1, 12 = 
9.78, Fig. 1C).  However, SCH29930 did not significantly block nicotine-induced 
hypothermia in 4 knockout mice (-2.99 + 0.17 compared to -3.05 + 0.280 C, NS, 
Fig. 1D).  
To compare tolerance profiles in Leu9’Ala, 4 KO, and WT mice, we 
recorded hypothermia induced by single daily injections of nicotine.  Figure 2A 
illustrates representative body temperature recordings in 4 KO and Leu9’Ala 
homozygous mice immediately after nicotine injection (2 mg/kg and 0.015 mg/kg, 
i.p. respectively) on exposure day 1, 4, or 7. Similar to our previous findings, 
selective activation of Leu9’Ala nAChRs with 0.015 mg/kg nicotine is sufficient for 
the development of tolerance. After 7 injections of nicotine over 7 days, nicotine-
induced hypothermia is decreased by 78.8 + 13.3% (Fig. 2B, p < 0.01, F1,12 = 
11.8).  To determine whether non-4* nAChRs are also necessary for a 
component of tolerance, we injected 4 KO animals with 2 mg/kg nicotine daily 
for seven days.  The hypothermic response of 4 KO mice measured after seven 
days of treatment was not significantly different than the response following the 
first injection; thus, tolerance did not develop (day 1 = -2.40 + 0.260 C compared 
to day 7 = -2.28 + 0.230 C, NS, Fig. 2A, and 2B).  The right-hand axis of Figure 
2B gives the scale for the parameters defined in Eqs. 1 and 2).
Figure 2C illustrates the tolerance profile of WT in response to daily 
injections of 2 mg/kg nicotine.  WT mice developed significant tolerance by the 
seventh injection (Day 1:  -4.74 + 0.170 C compared to Day 7:  -2.11 + 0.210 C, p 
< 0.001, F1,8 = 57.8).  This level of tolerance differed from tolerance profiles in 
Leu9’Ala or 4 KO mice by themselves (WT % attenuation between Days 1 and 
7:  49 + 4.8 % compared to 78 + 13.3 % in Leu9’Ala and -4.9 + 9.4 % in 4 KO 
mice, p < 0.01, F 2, 14 = 14.2).  The right-hand axis of Figure 2C gives the scale 
for the parameter defined in Eq. 3.  
Together, our data suggest that the nicotine-induced hypothermia in wild-
type mice is determined by the combination of activating both 4* and non-4* 
nAChRs, but that 4* nAChRs alone are primarily responsible for the magnitude 
of tolerance that develops with continued nicotine exposure.  To test this 
hypothesis, given by Eq. 4,, we summed the tolerance profiles from Leu9’ala and 
4 KO to predict the tolerance profile in wild-type animals (Eq. 4).  Figure 2D 
illustrates the normalized predicted tolerance profile compared to the actual 
tolerance profile from wild-type mice. The WT response was nearly identical to 
the predicted profile generated from the summed profiles of the two lines (Fig. 
2D).
Locomotor activity
Previously, we reported that selective activation of 4* nAChRs with nicotine in 
Leu9’Ala mice activates locomotor activity after multiple drug exposures.  This 
effect is blocked by mecamylamine and also by the D1 antagonist SCH23390 [2].  
Figure 3 illustrates dose-response relationships between nicotine and changes in 
locomotor activity in WT (Fig. 3A) and Leu9’Ala mice (Fig. 3B).  Selective 
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8activation of 4* nAChRs with 0.015 or 0.030 but not 0.01 or 0.0075 mg/kg 
nicotine in Leu9’Ala mice activates locomotion after multiple drug exposures.  WT 
mice exhibit no significant changes in activity after exposures to low doses of 
nicotine that induce activity in Leu9’Ala mice (Fig. 3A, 0.015 mg/kg nicotine).  
However, with larger doses, nicotine does alter activity in a dose dependent 
manner.  
To determine a dose of nicotine that elicits an effect on locomotor activity 
in 4 KO mice, we injected mice acutely with 0.5, 1.0 or 2.0 mg/kg nicotine.  
Compared to saline and consistent with previous reports (9, 15), neither 0.5 nor
1.0 mg/kg nicotine had a significant effect on locomotor activity; whereas 2.0 
mg/kg significantly suppressed activity similar to WT mice (p < 0.01. F1, 14 = 15.9 
Fig. 3C).  In addition, this suppression of nicotine was significantly blocked by 
mecamylamine, indicating that the effect was mediated via nAChR activation
(Fig. 3D).
Figure 4A and B depict the pattern of locomotor activity for 30 min 
immediately after saline injection, or after one or six single daily injections of 
nicotine in 4 KO and Leu9’Ala. Summing this activity in the Leu9’Ala mice 
illustrates that selective activation of 4* nAChRs by 0.015 mg/kg nicotine 
produces significant locomotor activation (Fig. 4D, Day 1:  452 + 79 counts 
compared to Day 6:  919 + 68 counts, p < 0.001, F = 19.9).  Conversely, a single 
injection of 2 mg/kg nicotine significantly suppresses activity in 4 KO mice (Fig. 
4A, 759 + 80 counts post saline compared to 336 + 61 counts post 2 mg/kg 
nicotine, p < 0.001, F = 17.76, Fig. 4C); and this activity suppression persists 
over the course of six daily injections (Fig. 4C). The right-hand axes of Figs. 4C 
and 4D present scales for the parameters N  and A  defined in Eqs. 5 and 6, 
respectively.  We injected wild-type mice with 2 mg/kg nicotine once daily for six 
days.  The first injection significantly suppressed locomotion (Fig. 4E).  By the 
sixth injection, nicotine-induced locomotor activity was significantly increased 
compared to the first injection (Day 1= 0.193 + 0.0318 compared to Day 6 = 
0.539 + 0.132, p < 0.05, F = 6.53).  
Fig. 4F presents the prediction of Eq. 7: nicotine-induced locomotion 
factors caused by simultaneous selective activation of 4 nAChRs and activation 
of non-4* nAChRs.  Eq 7 predicts that, in WT mice, daily nicotine injection will
initially suppress locomotion, then increase activity with each successive 
injection.  This prediction agrees well with the data of Fig. 4E. 
Discussion
This report introduces a new method to evaluate the contribution of a 
single receptor pathway to an observed drug-induced behavior.  The method 
requires the existence of two mutant strains: the KO strain allows one to evaluate 
the response due to the drug’s effect on other receptors; and a hypersensitive 
strain (admittedly available in only rare instances) allows one to induce the 
response due to selective activation of the receptor itself.  Furthermore the 
hypersensitive strain must have the same expression of the receptor, at the 
cellular and subcellular level; the Leu9’Ala strain meets these requirements(3, 
16). One then asks whether the behavior of the WT strain is the sum or product
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the hypersensitive strain. One certainly expects such an analysis to apply well at 
the level of electrophysiological data on single cells; but the present paper shows
that the analysis yields straightforward results when applied to physiological and 
behavioral responses at the whole-animal level.  It is important for such a 
straightforward analysis that all strains are on an isogenic background.  To avoid 
confounds produced by genetic variability, and to facilitate comparison between 
strains, both 4 KO and Leu9’Ala mice in the relevant experiments were back-
crossed to C57BL/6J mice for at least eight generations.  
Selective activation of 4* nAChRs with low doses of nicotine in Leu9’Ala
mice causes hypothermia.  At higher doses, nicotine also induces hypothermia in 
WT animals; and at still higher does, in mice that do not express 4* nAChRs
(Figure 1A).  While nicotine-induced hypothermia in both mutant strains is 
centrally mediated and sensitive to blockade by the noncompetitive nicotinic 
receptor antagonist, mecamylamine (Figure 1B, and (16)), only 4-mediated 
hypothermia is blocked by a D1 antagonist; thus the two hypothermic responses 
are pharmacologically distinct (Figure 1C and 1D). Based on these data, 
nicotine-induced hypothermia in wild-type mice is initiated by activation of at least 
two receptor subtypes--one containing 4 subunits, and the other(s) containing 
non-4 subunits. Note that the shift between KI and WT is much greater than the 
shift between WT and KO in nicotine-induced hypothermia; for instance, 1 mg/kg 
induces partial hypothermia in both WT and KO mice.  The latter point implies 
that the 4-dependent component is not necessary for nicotine-induced 
hypothermia.  On the other hand, the 4-dependent component displays 
tolerance in our experiments, while the 4-independent component does not.   
Interestingly, in 2 knockout mice nicotine-induced hypothermia responses 
resemble our data with 4 knockouts, consistent with the idea that hypothermia-
controlling 4* nAChRs, like most 4* nAChRs, also contain the 2 subunit(11).
Previously, we found that daily selective activation of 4* nAChRs in 
Leu9’Ala mice elicited tolerance to nicotine-induced hypothermia.  Nicotine
responses were attenuated by > 75 % by the seventh daily exposure.  However, 
when challenged with daily nicotine doses that produce hypothermia, WT
animals develop tolerance to a significantly lesser extent than Leu9’Ala mice.  
Figure 2 illustrates that this arises from at least two different nicotinic receptor 
dependent mechanisms.  The 4-mediated hypothermic component isolated in 
Leu9’Ala mice develops profound tolerance, whereas activation of the non-4* 
nAChR component in 4 KO mice does not change with repetitive nicotine 
exposure.  Summing these two independent responses predicts the wild-type 
tolerance response. Together, these data indicate that activation of 4* nAChRs 
is both necessary and sufficient for tolerance development of the hypothermic 
response.
In rats, single daily nicotine injections produce sensitization to the 
locomotor actions of nicotine(4, 5).  However, in WT mice, acute nicotine initially 
suppresses activity (Figures 3A, 4E).  With successive daily exposures, mice 
develop modest tolerance to this suppression.  Previous studies have shown that 
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mice lacking 2* nAChR expression are less sensitive to nicotine induced 
locomotor suppression at low doses of nicotine, but equally sensitive at high 
doses (18).  Similarly, we find that 4 KO animals are equally sensitive to 
locomotor suppression compared to WT animals at high nicotine doses (i.e. 2 
mg/kg).  Interestingly, selective activation of 4* nAChR in Leu9’Ala mice does 
not acutely suppress locomotor activity at the doses we have measured.  
Here we show that the biphasic WT locomotor profile likely arises from at 
least two combined nicotine actions with opposite effects on locomotor activity.  
Activation of non-4* nAChRs in 4 KO mice suppresses locomotor activity, and 
this effect persists with every daily exposure (Figures 4A and 4C).  Selective 
activation of 4* nAChRs, on the other hand, produces time- and exposure-
dependent increases in activity (Figures 4B and 4D).  In wild-type mice, these 
two mechanisms converge: non-4* nAChR activation initially suppresses 
activity but, with continued daily activation of 4* nAChRs, activity increases,
producing the observed locomotor patterns seen with repeated nicotine 
exposure.
Although this study does not directly explore mechanisms, the locomotor 
data, and their dependence on dopaminergic processes (16), are consistent with 
recent observations on 4* receptor changes during chronic nicotine at the 
cellular and circuit level in the midbrain (14).  On day 1, nicotine (1.5 - 2 mg/kg) 
suppresses locomotion equally in WT and 4 KO mice, consistent with the idea 
that nicotine-induced locomotor suppression at high doses involves non-42* 
receptors (10, 18), although the responding neurons are unknown.  Repeated 
nicotine applications would increase the number of functional 4* levels in some 
GABAergic neurons (14).  In response to nicotine, such upregulated 4* 
receptors would increase firing in the GABAergic neurons, inhibiting the 
downstream neurons that produce locomotor suppression via non-42
receptors; the latter receptors would not change sensitivity during repeated 
nicotine applications.  Thus, tolerance to nicotine-induced locomotor suppression 
would occur in a circuit. That selective activation of 4* receptors produces no 
initial locomotor suppression, but does eventually induce locomotor activation, 
may indicate that there is, initially, also ongoing suppression of locomotor activity, 
in keeping with present concepts about the complementary roles of the direct and 
indirect pathways in the basal ganglia. 
For our calculations, we elicited hypothermia and activity measurements 
with 2 mg/kg nicotine in 4 KO animals and 0.015 mg/kg in Leu9’Ala mice, doses 
that yield equivalent decreases in body temperature when acutely administered 
to drug-naïve animals of each strain.  Previously, we have found that nicotine-
induced hypothermia accurately reflects nicotine sensitivity to a number of 
behavioral and physiological responses.  However, it could be argued that the 
Leu9’Ala dose is near the plateau phase of the nicotine-hypothermia dose 
response relation for this strain, and that tolerance development may be due to a 
ceiling effect.  Such a ceiling mechanism is rendered unlikely by the observations 
that tolerance occurs at multiple hypothermia-inducing doses, including doses 
that do not saturate the dose-response relation (3). The combined 4 KO and 
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Leu9’Ala responses accurately account for WT tolerance to both hypothermia 
and locomotor suppression elicited by 2 mg/kg nicotine, a dose chosen because 
it would likely activate a majority of high sensitivity 4* nAChRs while also 
activating non-4* nAChRs to the same extent as an equal dose in 4 KO mice.
Together, our data indicate that 4* nAChR activation is necessary and 
sufficient for the development of tolerance as measured by daily injections of 
nicotine. 
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Figure Legends
Fig. 1:  Expression and pharmacology of nicotine-induced hypothermia in 
Leu9’Ala, 4 KO and WT mice:  A) Dose-response relation for WT (black 
squares), Leu9’Ala homozygous (black triangles) and 4 KO homozygous mice 
(open triangles) challenged with nicotine.  Each data point represents peak 
temperature drops from 4-10 animals, 15-40 min after the injection; see Tapper
et al., 2004.  B) Temperature response in 4 KO mice elicited by i.p. injection of 
2 mg/kg nicotine 15 min after either a saline (left, n = 5)) or mecamylamine (right, 
2 mg/kg, n = 6) injection.  C) Temperature response in Leu9’Ala 4 mice elicited 
by i.p. injection of 0.030 mg/kg nicotine 15 min after either a saline (left, n = 6)) or 
SCH29930 (right, 2 mg/kg, n = 8) injection. D)  Temperature response in 4 KO 
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mice elicited by i.p. injection of 2 mg/kg nicotine 15 min after either a saline (left, 
n = 6) or SCH29930 (right, 2 mg/kg, n = 6) injection.  Data are expressed as 
mean + SEM.  Significance was measured via one-way ANOVA (Tukey post-
hoc).  **p < 0.01, *** p < 0.001.
Fig. 2:  Hypothermia tolerance profiles in Leu9’Ala, 4 KO and WT mice.  A)  
Representative body temperature recordings from 4 KO (left) and Leu9’Ala 
(right) homozygous mice immediately after 1 (black trace), 4 (blue trace) or 7 (red 
trace) daily nicotine injections (i.p. 2 mg/kg and 0.015 mg/kg, respectively).  B. 
Nicotine-induced hypothermia tolerance profiles in Leu9’Ala homozygous and 4 
KO mice challenged with one daily injection (i.p.) of 0.015 mg/kg (Leu9’Ala, n = 
7) or 2 mg/kg (4 KO, n = 5-6) for seven days.  The scale of the right hand axis 
represents normalization to summed values from day 1 (Eqs 1, 2). C)  Nicotine-
induced hypothermia tolerance profile from WT mice injected with 2 mg/kg 
nicotine i.p. once daily for seven days (n = 5).  The scale of the right hand axis 
represents the response normalized to day 1 response (Eq. 3).  D)  Predicted 
(filled triangles, Eq. 4) and actual (open triangles) tolerance profile for wild-type 
mice, according to Eq. 4.  In all experiments, mice were injected with saline once 
daily for > 3 d prior to nicotine injections. Saline injections < 2º C changes in body 
temperature. Data are expressed as mean + SEM.  Significance was measured 
via one-way ANOVA (Tukey post-hoc).  *p < 0.05, **p < 0.01, *** p < 0.001
compared to first drug exposure.
Fig.3:  Nicotine-induced locomotor activity in WT, Leu9’Ala, and 4 KO mice.  A)
Locomotor responses in WT mice after 1, 3, and 6 daily injections of 0.015, 0.5, 
0.75, or 1.5 mg/kg nicotine B)  Locomotor responses in Leu9’Ala homozygous 
mice after 1, 3, and 6 daily injections of 0.0075, 0.010, 0.015, or 0.030 mg/kg 
nicotine.  In A) and B), each data point represents 30 min of activity immediately 
following drug injection. * p < 0.05, *** p < 0.001 compared to saline (day 0).  # p 
< 0.05 compared to first drug exposure in panel A and # p < 0.05 compared to 
0.0075 mg/kg day 6 in panel B.  C) Locomotor response to acute injection of 
saline or nicotine (0.50, 1.0, or 2.0 mg/kg) in 4 KO mice.  Each bar represents 
activity summed over 30 min immediately following injection.  D)  Locomotor 
responses in 4 KO mice injected with 2 mg/kg nicotine 15 min after an injection 
of either saline (left bar) or 2 mg/kg mecamylamine (middle bar). Mice that 
received mecamylamine prior to nicotine injection were injected with nicotine 
alone 24 hr later (right bar).  Data are expressed as mean ± SEM.  Significance 
was measured via one-way ANOVA (Tukey post-hoc).  Each bar represents 15 
min activity immediately following nicotine injection.  * p < 0.05, ** p < 0.01.   
Fig. 4: Prediction of nicotine-induced locomotor activity in WT mice via nicotine 
responses in 4 KO, and Leu9’Ala, homozygotes.  Activity pattern immediately 
following saline or 1, 3, or 6 daily nicotine exposures in A) 4 KO (2 mg/kg 
nicotine, i.p.) or B) Leu9’Ala (0.015 mg/kg nicotine i.p.) mice.  Activity counts 
were acquired at 30 sec intervals. Summed locomotor activity (L) was elicited by 
single daily i.p. injections of 2 mg/kg nicotine in C) 4 KO (n = 6) or D) 0.015 
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mg/kg injection in Leu9’Ala homozygous mice (n = 8).  See Eqs. (6) and (7) for 
definitions of A and N. E) Measured locomotor response (L) to single daily 
injections of 2 mg/kg nicotine in WT mice (n = 11).  F) Predicted daily locomotor 
responses to 2 mg/kg in WT mice (A(n)*N(n)), see Eq. 7).  Each bar graph 
represents the averaged sum of 30 min home cage activity immediately following 
injection. Baseline activity after saline injection is indicated by the dotted line.
Data are expressed as mean + SEM.  All animals were injected with saline once 
daily for at least 3 days prior to the start of the experiment. Significance was 
determined by one-way ANOVA (Tukey post-hoc).  *p < 0.05, ***p < 0.001
compared to baseline responses after a saline injection.
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